The Institute for Clinical and Economic Review reports that insurers improved coverage of drugs that ICER determines are fairly priced after the drug-pricing watchdog pointed out instances in which they were not meeting fair-access coverage criteria, but ICER says more needs to be done and it will continue reporting on drug formularies in the hopes of encouraging insurers to do a better job of covering fairly priced drugs. ICER typically reports on drug prices, and this first annual “Assessment of...